Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression

In the article by Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W entitled ‘Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression’, published in Haematologica supplement 2019 Jun;104(6):1202-1208, there is a small data error in the Online Supplementary Table S6, the number of low-risk FLIPI patients with POD24 in the G-chemo group percentage has been miscalculated, it should read (9.4) not (44.4).

Online Supplementary Table S6.POD24 and post-progression mortality rates, stratified by FLPI score category.